Why Your Generic Prescription Costs What It Does in Canada

The patent expires. Then what?

A pharmacist hands you a bottle of generic atorvastatin instead of Lipitor and you save money. How much money, and why that amount rather than some other amount, is a question most Canadians never ask. They should. Because the gap between what a generic drug could cost and what it does cost is filled by a tangle of federal bodies, provincial formularies, interprovincial negotiations, manufacturing economics, and political choices that have less to do with chemistry than with bureaucracy. Canada’s generics are cheaper than their brand-name equivalents, yes. But compared to the rest of the world, Canadian generic prices sit uncomfortably high, and understanding why that’s the case requires following the money through a system that very few people, including many prescribers, fully understand.

Generics now account for over 75% of prescription drug volume dispensed in Canada, according to the Patented Medicine Prices Review Board’s 2024 annual report. That market share makes them the backbone of the country’s pharmaceutical system. Yet per capita spending on generic drugs in Canada ranks second or third highest among comparable nations, depending on whether you adjust for purchasing power parity. The PMPRB’s own analysis of the Canadian generic market between 2018 and 2024 found that after initial price drops in early 2018, the Canadian price index for select oral solid generics plateaued at about 81 to 83% of its baseline level and hasn’t budged much since. That plateau tells a story worth examining.

The percentage-of-brand model and its hidden logic

When a brand-name drug loses patent protection and generic versions become available, Canadian provinces don’t let the market set the price. Instead, they use a blunt instrument: the generic gets listed on the provincial formulary at a fixed percentage of the brand-name drug’s price. Ontario, the country’s largest public drug plan, set this ceiling at 25% of the brand-name price in 2010, slashing it from the previous 50% cap that had been in place since 2006. British Columbia pegs most generics at 35% of the originator. New Brunswick sets oral solid generics at 25% but allows 35% for non-solid dosage forms, and prices certain molecules as low as 10, 15, or 18% of the brand price.

This system is easy to administer but carries a flaw that’s rarely discussed. The generic price is anchored to the brand-name price, which means if the brand-name price was inflated in the first place, the generic inherits that inflation. A brand-name drug priced at $4 per tablet yields a generic priced at $1 under Ontario’s 25% rule. But if the brand-name drug had been priced at $2, the same rule would produce a 50-cent generic. The anchor matters enormously, and it points to a question upstream: who controls the brand-name price?

That question leads to the PMPRB, the federal body tasked with ensuring patented medicine prices aren’t excessive. Until recently, the PMPRB compared Canadian prices against seven reference countries, a basket that included the United States and Switzerland, two of the most expensive pharmaceutical markets on earth. In July 2022, amended regulations swapped out those two countries and expanded the reference basket to eleven nations, adding Australia, Belgium, Japan, the Netherlands, Norway, and Spain. In theory, this should have pulled Canadian brand-name prices down, which would cascade into lower generic prices through the percentage-of-brand formula. In practice, the effect has been muted. The PMPRB’s new guidelines, released in June 2025 and taking effect January 1, 2026, allow the Canadian price to reach as high as the highest price among the eleven reference countries rather than the median. Researchers at York University have called this approach “industry-friendly,” and they aren’t wrong. When you benchmark to the ceiling instead of the middle, you give patented drug makers room to keep prices elevated, and that elevated floor feeds into what Canadians ultimately pay for generics.

Provinces negotiate, but not all the same way

One of the stranger features of Canadian drug pricing is that a generic metformin tablet can cost different amounts in different provinces. Each province and territory runs its own public drug plan with its own formulary, its own listing criteria, and its own willingness to negotiate. This fragmentation once meant that a manufacturer could charge Alberta one price and Saskatchewan another, and there was no mechanism to prevent it.

The pan-Canadian Pharmaceutical Alliance, or pCPA, was created in part to fix this problem. Established under the Council of the Federation, the pCPA pools the purchasing power of all thirteen provincial and territorial drug plans to negotiate prices collectively. By April 2025, the pCPA reported annualized savings of $935 million on generic drugs alone, with total savings across all drugs reaching nearly $4.9 billion. Those are real numbers. But the pCPA’s power has limits. It negotiates framework agreements with the Canadian Generic Pharmaceutical Association rather than drug-by-drug tenders, and those agreements rely on the voluntary cooperation of manufacturers. The current three-year pricing initiative, renewed in October 2023, sets the pan-Canadian Tiered Pricing Framework that assigns a maximum allowable list price based on the number of generic competitors for a given molecule. When a first generic enters the market, the price can be as high as 75% or even 85% of the brand. As more competitors arrive, the price drops in tiers, eventually landing at 25%. Under the 2023 renewal, new single-source generics that enter the framework automatically drop to 55% of the brand reference price after three months of public funding.

The tiered system is a reasonable attempt to balance market viability with affordability, but it contains an important tension. For drugs with small patient populations or complex manufacturing requirements, fewer generic manufacturers will enter the market, which means the price stays stuck in the higher tiers. The framework essentially acknowledges that not all generics are created equal, and that some will remain expensive because nobody else wants to make them.

Why some generics cost more than others

The popular image of a generic drug is simple: the patent expires, a factory stamps out copies, prices plummet. That image is accurate for oral solid dosage forms of widely used molecules like metformin or amlodipine, where dozens of manufacturers compete globally and active pharmaceutical ingredient suppliers in India and China can produce the API at pennies per dose. But it falls apart for complex generics: modified-release formulations, transdermal patches, injectables, inhalation products, and drugs with narrow therapeutic indexes where tiny variations in blood levels can affect efficacy or safety.

These complex products carry manufacturing costs that the simple-generic model doesn’t capture. A modified-release tablet requires proprietary coating technology or matrix systems. An injectable demands sterile manufacturing facilities with far higher capital and compliance costs. And every generic, complex or not, must pass Health Canada’s bioequivalence requirements, which demand clinical studies showing that the generic product delivers the same amount of drug into the bloodstream at the same rate as the brand-name reference product, within a 90% confidence interval of 80 to 125% for key pharmacokinetic parameters. Those studies cost money. For complex generics, they cost substantially more, and the manufacturer must absorb those costs before selling a single tablet.

Then there’s the API question. The global supply of active pharmaceutical ingredients has concentrated to a striking degree. China accounts for roughly 70% of API imports globally, and India, the world’s largest finished-dose generic manufacturer, sources approximately two-thirds of its own API needs from Chinese suppliers. This concentration creates both price vulnerability and supply risk. API production costs rose 25 to 30% between 2022 and 2025, driven by energy costs and chemical input inflation. Canadian generic manufacturers, who import the vast majority of their APIs, absorb those cost increases, and the math doesn’t always work out at the price points provincial formularies demand. Health Canada reported 3,098 drug shortages in fiscal year 2023-24, a 15% jump from the prior year, and Canada’s small market size, representing roughly 2% of global drug and medical device sales, means it’s often last in line when supplies tighten.

Canada’s uncomfortable international position

Canadians tend to assume their drug prices are reasonable. After all, they’re not Americans. That comparison flatters us. When the PMPRB compares Canadian generic prices to those in other developed countries, the results aren’t reassuring. Average generic drug prices across the original PMPRB7 reference countries were 11% lower than in Canada, and median prices were 30% lower. The board’s own analysis estimated that if public drug plans had paid median foreign prices for their top-selling generics, they could have saved nearly half a billion dollars in a single fiscal year. More recent data from the PMPRB’s 2024 market trends analysis puts Canadian per capita generic spending at second or third highest among peer nations, depending on the exchange rate adjustment used.

How did this happen? Part of the answer is structural. Canada’s percentage-of-brand pricing model ties generic prices to brand-name prices that were themselves set high. Part of the answer is political: provinces have historically avoided competitive tendering for generic drugs, preferring negotiated frameworks that guarantee supply security at the cost of higher prices. The Competition Bureau flagged this trade-off as early as 2007, recommending that public plans move toward competitive tendering, and again in a 2008 follow-up report. Nearly two decades later, that recommendation remains largely unimplemented. The current pCPA-CGPA agreement, which includes a provision to avoid competitive tendering, expires in 2026, and whether the next agreement changes that calculus will be a significant test of political will.

Pharmacare and the big question ahead

The Pharmacare Act came into force in October 2024, establishing a framework for a first phase of universal, single-payer, first-dollar drug coverage. British Columbia signed a bilateral agreement with the federal government in March 2025, backed by up to $670 million over three years, providing full coverage for eligible contraceptives, diabetes medications, and hormone replacement therapy starting March 1, 2026. But the program’s expansion has stalled since the federal election in April 2025, and whether other provinces will sign bilateral agreements remains an open question as of early 2026.

For generic drug pricing, pharmacare’s implications are substantial but uncertain. A single national payer would, in principle, command far greater bargaining power than thirteen separate provincial plans. That leverage could drive generic prices down to levels closer to international norms. New Zealand’s PHARMAC model, which uses competitive tendering for a national formulary, routinely achieves generic prices that are a fraction of Canada’s. But pharmacare could also reduce the number of generic manufacturers willing to serve the Canadian market if prices fall below the point where production is viable, especially for low-volume or complex molecules. The tension between affordability and supply security is real, and the semaglutide example illustrates it: several manufacturers submitted generic applications to Health Canada in 2025, with prices expected at 60 to 70% below the brand, and once three generic competitors are on the market, Canadian policy will drive list-price discounts of about 65%. Whether all those manufacturers stick around at those prices is another matter.

What actually needs to change

The system that prices Canadian generics is a product of decades of incremental policy decisions, each one reasonable in isolation, that collectively produce an outcome nobody would design from scratch. Provincial formularies anchor to brand-name prices that federal regulators allow to be set high. Interprovincial negotiations produce savings but avoid the competitive mechanisms that could produce deeper ones. Small market size and API import dependency create cost pressures that formulary prices don’t always accommodate. And the emerging pharmacare framework introduces both opportunity and risk that policymakers haven’t fully worked through.

Three changes would make the biggest difference. First, the PMPRB should benchmark brand-name prices to the median of its reference countries rather than the highest, which would lower the anchor that generic prices inherit. Second, the pCPA’s next agreement with the generic industry should pilot competitive tendering for high-volume molecules where supply security isn’t at risk, rather than extending the blanket avoidance of tendering that has been in place for over a decade. Third, pharmacare negotiations should learn from international models that balance price competition with supply guarantees, structuring tenders to ensure at least two or three suppliers remain viable for every molecule. The York University critique of the PMPRB’s 2025 guidelines is right to raise the alarm about an approach that, despite years of promised reform, still leaves Canadian drug prices near the top of the international rankings. Canadians deserve a system that’s as smart as its aspirations, and right now the gap between those two things remains too wide.

---

References

1. Patented Medicine Prices Review Board. Annual Report 2024. Government of Canada. www.canada.ca/en/patented-medicine-prices-review/services/annual-reports/annual-report-2024.html

2. PMPRB. Canadian generic market trends and international comparison, 2018-2024. Government of Canada. www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/canadian-generic-market-trends.html

3. PMPRB. PMPRB releases new Guidelines to monitor and review drug prices. June 2025. www.canada.ca/en/patented-medicine-prices-review/news/2025/06/pmprb-releases-new-guidelines-to-monitor-and-review-drug-prices.html

4. York University. “Canada’s new drug pricing guidelines are industry-friendly.” The Conversation, July 28, 2025. theconversation.com/canadas-new-drug-pricing-guidelines-are-industry-friendly-261062

5. Pan-Canadian Pharmaceutical Alliance. Generic drug framework. www.pcpacanada.ca/generic-drug-framework

6. pCPA/CGPA. New pricing initiative for generic drugs, October 2023. www.pcpacanada.ca/node/22460

7. PMPRB. Generic and Biosimilar Pricing Policies for Canadian Public Drug Plans. Government of Canada. www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/supporting-information/generic-biosimilar-pricing-policies.html

8. Competition Bureau Canada. Benefiting from Generic Drug Competition in Canada: The Way Forward, 2008. competition-bureau.canada.ca/en/benefiting-generic-drug-competition-canada-way-forward

9. Health Canada. Drug shortages in Canada: Fiscal year 2023 to 2024 in review. www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/2023-2024-review.html

10. Canadian Generic Pharmaceutical Association. International Pricing and Canada’s Generic Prescription Medicines, 2023. canadiangenerics.ca/wp-content/uploads/2023/12/CGPA_International-Pricing-and-Canadas-Generic-Prescription-Medicines-2023.pdf

11. Government of British Columbia. National pharmacare in B.C., March 2025. gov.bc.ca/nationalpharmacare

12. PMPRB. Generic Drugs in Canada: International Price Comparisons and Potential Cost Savings. www.pmprb-cepmb.gc.ca/view.asp?ccid=870

13. Canadian Centre for Policy Alternatives. “Prescription drug prices are very likely to increase in Canada.” www.policyalternatives.ca/news-research/prescription-drug-prices-are-very-likely-to-increase-in-canada/

14. Health Canada. Health Canada’s plan to address health product shortages, 2024 to 2028. www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/plan-2024-2028.html